Reported Tuberculosis in the United States, 2018
Table 51. Tuberculosis Cases and Percentages, by Completion of Tuberculosis Therapy (COT): Reporting Areas, 20161
| Reporting Area | Total Cases | Therapy ≤1 Year Indicated2,3,4 | Therapy >1 Year Indicated3,5 | |||
|---|---|---|---|---|---|---|
| No. | COT ≤1 year(%) | COT(%) | No. | COT(%) | ||
| United States | 9,253 | 7,582 | (89.2) | (95.6) | 500 | (93.2) |
| Alabama | 112 | 97 | (86.6) | (94.8) | 1 | (100.0) |
| Alaska | 57 | 54 | (88.9) | (90.7) | 0 | … |
| Arizona | 188 | 135 | (87.4) | (95.6) | 8 | (100.0) |
| Arkansas | 91 | 70 | (78.6) | (85.7) | 3 | (100.0) |
| California | 2,058 | 1,647 | (88.2) | (96.4) | 106 | (91.5) |
| Colorado | 64 | 46 | (89.1) | (91.3) | 3 | (100.0) |
| Connecticut | 52 | 41 | (97.6) | (97.6) | 4 | (100.0) |
| Delaware | 16 | 14 | (100.0) | (100.0) | 1 | (100.0) |
| District of Columbia | 25 | 19 | (94.7) | (100.0) | 3 | (100.0) |
| Florida | 639 | 535 | (93.1) | (96.6) | 29 | (93.1) |
| Georgia | 302 | 243 | (89.3) | (95.5) | 14 | (85.7) |
| Hawaii | 119 | 102 | (99.0) | (100.0) | 8 | (100.0) |
| Idaho | 18 | 15 | (93.3) | (93.3) | 0 | … |
| Illinois | 341 | 275 | (92.0) | (97.8) | 21 | (95.2) |
| Indiana | 109 | 91 | (92.3) | (98.9) | 5 | (100.0) |
| Iowa | 48 | 40 | (87.5) | (92.5) | 4 | (100.0) |
| Kansas | 39 | 37 | (91.9) | (100.0) | 1 | (100.0) |
| Kentucky | 91 | 77 | (96.1) | (100.0) | 3 | (100.0) |
| Louisiana | 128 | 112 | (75.9) | (91.1) | 4 | (25.0) |
| Maine | 23 | 21 | (95.2) | (100.0) | 0 | … |
| Maryland | 221 | 182 | (93.4) | (97.8) | 14 | (100.0) |
| Massachusetts | 190 | 156 | (88.5) | (98.1) | 8 | (100.0) |
| Michigan | 133 | 115 | (94.8) | (97.4) | 5 | (80.0) |
| Minnesota | 168 | 138 | (94.2) | (95.7) | 16 | (93.8) |
| Mississippi | 61 | 47 | (89.4) | (95.7) | 7 | (71.4) |
| Missouri | 99 | 88 | (78.4) | (81.8) | 3 | (100.0) |
| Montana | 4 | 4 | (100.0) | (100.0) | 0 | … |
| Nebraska | 28 | 25 | (56.0) | (72.0) | 3 | (66.7) |
| Nevada | 55 | 43 | (95.3) | (95.3) | 4 | (100.0) |
| New Hampshire | 15 | 10 | (100.0) | (100.0) | 3 | (100.0) |
| New Jersey | 294 | 242 | (93.8) | (97.9) | 13 | (100.0) |
| New Mexico | 39 | 29 | (89.7) | (96.6) | 2 | (100.0) |
| New York State6 | 202 | 161 | (95.7) | (100.0) | 16 | (93.8) |
| New York City | 556 | 447 | (93.3) | (97.3) | 52 | (94.2) |
| North Carolina | 219 | 189 | (91.0) | (96.3) | 15 | (100.0) |
| North Dakota | 22 | 21 | (90.5) | (95.2) | 1 | (100.0) |
| Ohio | 142 | 117 | (76.9) | (84.6) | 9 | (88.9) |
| Oklahoma | 78 | 59 | (94.9) | (96.6) | 3 | (100.0) |
| Oregon | 70 | 59 | (79.7) | (89.8) | 4 | (100.0) |
| Pennsylvania | 173 | 142 | (77.5) | (92.3) | 12 | (91.7) |
| Rhode Island | 12 | 8 | (87.5) | (100.0) | 3 | (100.0) |
| South Carolina | 102 | 83 | (94.0) | (97.6) | 8 | (100.0) |
| South Dakota | 12 | 9 | (88.9) | (88.9) | 1 | (100.0) |
| Tennessee | 103 | 86 | (95.3) | (100.0) | 7 | (100.0) |
| Texas | 1,247 | 1,046 | (84.8) | (93.2) | 51 | (88.2) |
| Utah | 20 | 18 | (94.4) | (100.0) | 0 | … |
| Vermont | 6 | 5 | (100.0) | (100.0) | 0 | … |
| Virginia | 203 | 172 | (92.4) | (97.1) | 10 | (100.0) |
| Washington | 204 | 165 | (92.1) | (95.8) | 9 | (100.0) |
| West Virginia | 14 | 11 | (81.8) | (90.9) | 1 | (100.0) |
| Wisconsin | 40 | 34 | (85.3) | (100.0) | 2 | (100.0) |
| Wyoming | 1 | 0 | … | … | 0 | … |
| American Samoa7 | 1 | 1 | (0.0) | (0.0) | 0 | … |
| Fed. States of Micronesia7 | 134 | 124 | (96.0) | (96.0) | 2 | (100.0) |
| Guam7 | 73 | 64 | (84.4) | (87.5) | 2 | (100.0) |
| Marshall Islands7 | 178 | 157 | (57.3) | (58.0) | 3 | (66.7) |
| N. Mariana Islands7 | 28 | 25 | (92.0) | (92.0) | 0 | … |
| Puerto Rico7 | 69 | 52 | (88.5) | (96.2) | 3 | (66.7) |
| Republic of Palau7 | 23 | 19 | (84.2) | (89.5) | 0 | … |
| U.S. Virgin Islands7 | 0 | 0 | … | … | 0 | … |
1Most recent year for which data are available.
2In the United States, initial isolate susceptible to rifampin (n = 5,635) or susceptibility unknown (n = 98); culture negative (n = 1,476); culture status unknown (n = 359).
3Number of cases among persons alive at diagnosis, with an initial regimen of ≥1 drug prescribed. Percentages for United States overall are based on 52 reporting areas (50 U.S. states, New York City, and the District of Columbia).
4Therapy ≤1 year indicated among persons alive at diagnosis with an initial regimen of ≥1 drug prescribed, who did not die ≤1 year after initiating therapy. Excludes persons with initial isolate rifampin-resistant, or patient with bone or joint disease, meningeal disease or disease of the central nervous system, or pediatric patient (aged ≤14 years) with miliary disease or positive blood culture or a positive nucleic acid amplification test on a blood specimen, and those who moved out of the country ≤1 year after initiating treatment.
5Initial isolate rifampin-resistant, or patient with meningeal disease or bone or joint disease, or disease of the central nervous system, or pediatric patient (aged ≤14 years) with miliary disease or positive blood culture or a positive nucleic acid amplification test on a blood specimen, and those who did not move out of the country or die during treatment.
6Excludes New York City.
7Not included in U.S. totals.
Note: See Technical Notes.
Ellipses (…) indicate that the percentage cannot be calculated, and the denominator is 0.
